Willeke Ros

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord et al. · Journal of Clinical Oncology · 2019 · 1K citations · Full text

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <scp>KEYNOTE</scp>‐158 and <scp>KEYNOTE</scp>‐028 studies

Sarina A. Piha‐Paul, Do‐Youn Oh, Makoto Ueno et al. · International Journal of Cancer · 2020 · 485 citations · Full text

Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.

Hyun Cheol Chung, José A. López-Martín, Stephen Chuan-Hao Kao et al. · Journal of Clinical Oncology · 2018 · 206 citations

Sclc Pts, Immunology, Immunoediting +16

Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).

Josep Tabernero, Ignacio Melero, Willeke Ros et al. · Journal of Clinical Oncology · 2017 · 164 citations

Atezolizumab 1200, Immunology, Immunotherapeutics +19

Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.

Yung‐Jue Bang, Makoto Ueno, David Malka et al. · Journal of Clinical Oncology · 2019 · 132 citations

Immunology, Immunoediting, Pathology +18